RT Journal Article
SR Electronic
T1 Hepatitis C virus: Here comes all-oral treatment
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 159
OP 172
DO 10.3949/ccjm.81a.13155
VO 81
IS 3
A1 Dugum, Mohannad
A1 O’shea, Robert
YR 2014
UL http://www.ccjm.org/content/81/3/159.abstract
AB Treatment for chronic hepatitis C virus (HCV) infection is evolving rapidly. The approval in 2013 of two new directacting antivirals—sofosbuvir (a polymerase inhibitor) and simeprevir (a second-generation protease inhibitor)— opens the door for an all-oral regimen, potentially avoiding interferon and its harsh side effects. Other direct-acting antivirals are under development.